All great things begin with a dream…our dream was that no one dies from an anaphylaxis episode, increasing the consciousness and knowledge about anaphylaxis worldwide”

Behind every idea there is a story

One day, a man went for a walk in the woods and meanwhile he decided to have a snack. This snack contained an allergic product for him, and he suffered an anaphylaxis reaction. He had an epinephrine auto-injector with him but, under pressure, many things came to his mind: Was the drug in good condition? What did he have to do? Should he make a phone call first? He was confused, and before taking any action, he vanished. Luckily, a dog from a nearby house found him and the barks alerted someone that called the emergency services, who saved his life.

Once this man told his story to Anna Sala, she realised that carrying an epinephrine auto-injector is not enough to save someone’s life. Owning an epinephrine auto-injector involves many challenges. She shared her worries with Adrian Curran and together they came with an idea: anAPPhylaxis!


From the idea to the reality

Adan Medical Innovation was born in July 2013 between Silicon Valley and Barcelona. The idea became a reality during an Innovation program (Imagine Creativity Center) in Silicon Valley, were the co-founders Anna Sala and Adrian Curran reframed all the concerns that the patients who suffer allergic reactions have and prototyped the idea, defining the next steps. The first thing was to put together an appropriate team, with the main aim of “improving the quality of life of patients that suffer anaphylaxis”.

“If you want to go fast go alone, but if you want to go far go together “. With this in mind, Adan Medical Innovation wanted to be a different health tech company, and created a multidisciplinary team with experts in all the different areas that the project needed (clinical, regulatory, hardware&software, quality control, design…), also including patients, to be able to bring excellence to the project.

During these years, the team has grown and worked very hard, always with the purpose to improve the development of our solution. The first clinical trial with a device evaluating its usefulness for the management of anaphylaxis has been completed in one of the largest hospitals in Europe. Currently, with the improved solution and the clinical trial completed, we are working on the last steps to bring anAPPhylaxis to the market, which involve regulatory clearance. In addition, we are also working with new technologies to bring our solution to public spaces using IOT, to be able to improve the quality of life of all potential patients and increase the awareness and knowledge of the disease around the world.